Drug profile · INN
somatrogon-ghla
NGENLA
somatrogon-ghla (NGENLA) is a growth hormone receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — somatrogon-ghla
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
somatrogon-ghla (NGENLA) is a growth hormone receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Growth hormone receptor agonist
Primary target: Growth hormone receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is somatrogon-ghla?
somatrogon-ghla (NGENLA) is a growth hormone receptor agonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for somatrogon-ghla?
NGENLA is a marketed brand name for somatrogon-ghla. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of somatrogon-ghla?
somatrogon-ghla has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.